All In MedTech

FDA Clearance Tracker · P190020

BioFreedom Drug Coated Coronary Stent System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 14, 2022 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 14, 2022

Approval withdrawn

Time to decision

972 days

Received Aug 16, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P190020
Device name
BioFreedom Drug Coated Coronary Stent System
Applicant location
Wilmington, DE
Received
Aug 16, 2019
Decided
Apr 14, 2022
Decision
Approval withdrawn

Device type

Device class
Class III

Every decision under product code NIQ

FDA's approval statement

As written in FDA's record.

Approval for the BioFreedom Drug Coated Stent System. This device is indicated for improving coronary luminal diameter in patients at high risk for bleeding with symptomatic ischemic heart disease due to de novo lesions of length <= 32 mm in native coronary arteries with a reference diameter ranging between 2.25 mm and 4.0 mm.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NIQ. The earliest in FDA's data is P020026, decided Apr 24, 2003.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Biosensors International USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.